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The internet of health care things enables a remote connection between health care professionals and patients wearing smart
biosensors. Wearable smart devices are potentially affordable, sensitive, specific, user-friendly, rapid, robust, lab-independent,
and deliverable to the end user for point-of-care testing. The datasets derived from these devices are known as digital biomarkers.
They represent a novel patient-centered approach to collecting longitudinal, context-derived health insights. Adding automated,
analytical smartphone applications will enable their use in high-, middle-, and low-income countries. So far, digital biomarkers
have been focused primarily on accelerometer data and heart rate due to well-established sensors originating from the consumer
market. Novel emerging smart biosensors will detect biomarkers (or compounds) independent of a lab and noninvasively in sweat,
saliva, and exhaled breath. These molecular digital biomarkers are a promising novel approach to reduce the burden from 2 major
infectious diseases with urgent unmet needs: tuberculosis and infections with multidrug resistant pathogens. Active tuberculosis
(aTbc) is one of the deadliest diseases from an infectious agent. However, a simple and reliable test for its detection is still missing.
Furthermore, inappropriate antimicrobial use leads to the development of antimicrobial resistance, which is associated with high
mortality and health care costs. From this perspective, we discuss the innovative approach of a noninvasive and lab-independent
collection of novel biomarkers to detect aTbc, which at the same time may additionally serve as a scalable therapeutic drug
monitoring approach for antibiotics. These molecular digital biomarkers are next-generation digital biomarkers and have the
potential to shape the future of infectious diseases.
(J Med Internet Res 2021;23(8):e25907) doi: 10.2196/25907
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Introduction
A biomarker is defined as “a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention” by the National Institutes of Health
Biomarkers Definitions Working Group [1]. Biomarkers are
mostly collected from standard biofluids such as blood and
urine, among others [2,3]. Compared with unspecific
inflammatory markers such as C-reactive protein (CRP), more
specific biomarkers such as bacterial culture support diagnosis
and disease monitoring [2]. The emergence of smart devices as
part of the internet of health care things allows for connecting
a patient with health care workers in a location- and
lab-independent way [4]. Recording a patient’s health status
independent of a lab and remotely provides a novel entity for
health and disease data, referred to as a digital biomarker [5].
Smart biosensors collect digital biomarkers such as
accelerometer data, heart rate, and body temperature mostly in
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a noninvasive way. By connecting smart biosensors to automated
analytical smartphone applications, digital biomarkers are
disrupting standard operating procedures in patient monitoring
[6]. The data collected are subsequently stored, shareable, and
therefore serve as an outbreak detection network for infectious
diseases as described by Tom-Aba et al [7].
Smart biosensors from the consumer market that monitor a
patient’s activity, electrocardiogram, heart rate, and other
parameters are increasingly available as certified medical
devices [8]. The potential to continuously record
patient-centered information from daily life will provide deeper
insight into health and disease. Investigations into digital
biomarkers have been focused on health measurements such as
activity and heart rate due to the broad availability of
accelerometer sensors. Patients with multiple sclerosis as well
as those with Parkinson’s disease–related tremors are subjects
of current clinical research [9,10], and studies are also
investigating smart device–based automated algorithms to screen
for atrial fibrillation using photoplethysmographic rhythm
analysis [11].
Point-of-care testing (POCT) provides personalized and
actionable case identification near a patient’s location [12].
POCT needs to match the ASSURED criteria according to the
World Health Organization (WHO): (1) affordable, (2) sensitive,
(3) specific, (4) user-friendly, (5) rapid and robust, (6)
equipment-free, and (7) deliverable to the end user [13]. POCT
supports health care professionals in high-income countries, as
well in middle- and low-income countries with restricted health
care infrastructure [14,15]. The most significant barriers for
broad use of POCT are lack of training, increased patient waiting
time, and lack of availability [16]. Wearable devices linked to
automated smartphone applications can be applied at home
irrespective of the distance to the nearest health care facility
[17]. Novel biosensors will provide the next generation of digital
biomarkers by noninvasively detecting molecular feedback
[18,19]. The increasingly available smartphone-based biosensors
meet the WHO ASSURED criteria and will shape the future of
managing infectious diseases around the globe.
From this perspective, we explored novel smartphone-based
biosensors to analyze sweat, saliva, and exhaled breath for 2 of
the main global issues in infectious diseases. We discuss the
potential of molecular digital biomarkers in patients with active
tuberculosis (aTbc), 1 of the 3 important epidemics [20]. In
addition, we will give a perspective on the use of smart
biosensors for noninvasive, personalized, pharmacologic
monitoring in patients treated with antibiotics. Antibiotic drug
resistance is a threat to global health and a major public health
issue [21]. Finally, we will summarize the remaining limitations
that have prevented these approaches from being clinically
implemented.
Novel Biosensors for Sweat, Saliva, and
Exhaled Breath Analysis
Biofluids such as sweat, saliva, and exhaled breath are
noninvasively collectable and represent a promising pool of
continuously available molecular biomarkers. So far, sweat,
saliva, and exhaled-breath samples have mostly been analyzed
using laborious and expensive mass spectrometry [22-24]. Smart
biosensors coupled with smartphone applications are
increasingly available and allow for lab-independent analysis
[25-27]. Smart biosensors connect patients and health care
professionals remotely, mostly through Bluetooth or WiFi and
may have a global impact in high- as well as in middle- and
low-income countries with less available health care
infrastructure [4].
Sweat Sensors
Sweat samples are often restricted to low-volume, low-molecule
concentrations and need sample stabilization. Noninvasive,
lab-independent, on-skin sweat analysis is increasingly available.
There are electrochemical-based [28] (Figure 1A),
enzyme-linked immunoassay (ELISA)–based [29], and
aptameric-based sensors [30], among others. The clinical
implementation of sweat biosensors has been restricted, mostly
due to unsolved challenges such as sensor stability and low
biomarker concentrations. The first clinical tests were
successfully conducted using a sweat sensor that detects uric
acid as well as tyrosine as described by Yang et al [31].
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Figure 1. Next–generation biosensors in health care: (A) on-skin sweat biosensor for sweat analysis by Reeder et al [27]; (B) tooth-mounted biosensor
for saliva analysis by Tseng et al [25]; and (C) e-nose for exhaled breath analysis by Aeonose [32]. Permission to reproduce the images was obtained
from the respective publishers/authors.
Saliva Sensors
A biosensor for in-mouth analysis of saliva has been developed
by Tseng et al [25] (Figure 1B). This small sensor is designed
to be tooth-mounted and allows for continuous, lab-independent
saliva analysis. The functionality of this trilayer sensor was
tested in vivo by detecting glucose in different conditions such
as dry mouth, after drinking tap water, and after drinking apple
juice. Analysis is conducted in combination with a portable
vector analyzer attached to a tablet or cell phone. Reliable and
stable detection of glucose in vivo was demonstrated for more
than 1 week.
Exhaled Breath Sensors
Biosensors to analyze exhaled breath can be summarized under
the term “electric nose” (EN) [26] (Figure 1C). The applicability
ranges from health care [33], the food and beverage industry
[34], to general monitoring [35]. EN can be compared to the
human sense of smell, as the sensor array represents the human
nose and data analysis represents the human brain. There are
different sensor entities such as low-cost metal oxide sensors
performing well at high temperatures; fast and reliable
conducting polymer sensors responding to odors; and sensitive,
rapid, and stable quartz crystal microbalance [26]. EN has
already been clinically validated [36].
Perspective on Smart Biosensors
Smart biosensors are promising novel approaches to overcome
the current remote patient monitoring issues such as lab
dependence, laborious sample preparation, and time delays. As
analysis can be automated, biosensors will be intuitively easy
to handle. The novel opportunity to record continuous molecular
feedback will provide novel high-resolution information about
health and disease. Nevertheless, easy and continuous health
measurements lead to novel issues such as massive amounts of
recorded health data and the challenge of interpreting it
adequately. Further, due to remaining challenges, such as sensor
stability, sample standardization, and detecting low biomarker
concentrations, an easy, lab-independent method of detecting
complex molecules (eg, proteins) remains an unmet target and
requires substantial development and validation efforts. Smart
biosensors represent a great potential to solve remaining health
care challenges in high-, middle-, and low-income countries.
For successful clinical implementation, it will be essential to
bring together all stakeholders such as engineers, health care
workers, and business partners early, to enable a cost-effective
and valuable solution.
Novel Biomarkers in Sweat, Saliva, and
Exhaled Breath to Detect Active
Tuberculosis
aTbc is caused by infection with a member of the
Mycobacterium tuberculosis complex. aTbc is endemic in India,
Indonesia, China, Nigeria, Pakistan, and South Africa. From
2000 to 2016, an estimated 53 million people died from
tuberculosis infection, and about 10.4 million people were
infected per year [20]. To fulfil the WHO End TB Strategy,
novel diagnostic markers and devices are urgently needed, as
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a reliable, straightforward, fast diagnostic test is still lacking
[37,38]. Present diagnostic tests are mostly sputum-dependent,
which is a significant limitation given that many patients do not
produce sputum [39-41]. If sputum cannot be collected
spontaneously, an invasive bronchoalveolar lavage is indicated
to confirm the diagnosis. Due to limitations of current tests, the
patient may remain in contact isolation for weeks until diagnosis.
A straightforward test to detect aTbc would enable earlier
diagnosis and treatment initiation and therefore potentially lead
to a lower transmission rate and decreased morbidity, mortality,
and health care costs [42-44].
Biomarkers in Sweat
By using mass spectrometry analysis, Adewole et al [45]
detected 26 specific proteins in the sweat of patients diagnosed
with aTbc (Table 1). The researchers were able to differentiate
between patients with aTbc, patients with a differential diagnosis
such as pneumonia or lung cancer, and healthy controls by
taking into account the protein expressions in sweat.
Differentiation between the groups was even possible for
patients with a history of adequately treated aTbc. The proteomic
sweat analysis revealed specific molecules for aTbc such as
C1q subcomponent, which has been associated with aTbc [46].
Table 1. Overview of next-generation digital biomarkers in sweat, saliva, and exhaled breath for infectious diseases.





HCC-1, and fibrinogen [47]
Complement C1q subcomponent





macrolides (eg, clarithromycin), tetracycline








Jacobs et al [47] investigated saliva samples from patients
presenting with suspected aTbc prior to diagnosis. Patients were
subsequently classified using clinical, radiological, and
laboratory findings as having aTBc or other respiratory diseases.
A 5-biomarker signature detected by Luminex multiplex
immunoassay including markers such as interleukin-1β (Table
1) enabled detection of aTbc with a sensitivity of 88.90% and
a specificity of 89.75%. Extending the biomarker range led to
a sensitivity of 100% and a specificity of 95% (in the absence
of HIV) and detected a treatment response from the host after
adequate treatment initiation [47].
Biomarkers in Exhaled Breath
In 1998, Wang et al [52] investigated patients with aTbc and
described different levels of nitric oxide in exhaled breath as a
potential diagnostic marker using chemiluminescence analysis.
By gas chromatographic and mass spectrometric analysis,
Phillips et al [48] detected further promising volatile components
to differentiate between aTbc and controls (Table 1). Further
Nakhleh et al [53] investigated 198 samples from aTbc patients
and healthy controls. Of them, 138 samples with known
diagnosis were used for unsupervised sensor training, and 60
undefined samples were used for blind validation. In addition,
combining exhaled analysis by nanomaterial-based sensors with
unsupervised machine learning led to a promising, noninvasive
detection tool [54]. Further investigation supported this
approach, by using “breathprints” for the detection of M.
tuberculosis [55].
Perspective on Digital Biomarkers to Detect aTbc
Detecting and diagnosing aTbc remain laborious and time
consuming. Increasing resistance against antimicrobial therapies
is further aggravating the burden caused by the disease. As aTbc
is mainly endemic in low- and middle-income countries with
rather restricted health care access, novel approaches to detect,
diagnose, and treat aTbc are needed. An increasing amount of
basic research has been conducted recently to define novel aTbc
biomarkers. Next to well-known proteins such as C1q and CRP,
novel and promising proteins have been explored in sweat,
saliva, and exhaled breath of aTbc patients that need further
confirmation of value [45]. Smart biosensors for detecting
specific aTbc molecules in the aforementioned biofluids have
not been applied yet, while e-NOSE has to be considered as an
exception [56,57]. Therefore, exhaled breath is the most
advanced biofluid when it comes to clinical implementation,
while sweat and saliva remain very promising concepts.
Nevertheless, exhaled breath may be restricted to pulmonary
tuberculosis only. Therefore, sweat and saliva analysis may
provide deeper systematic insights into not only pulmonary but
also extrapulmonary aTbc.
Detecting Antibiotics in Sweat, Saliva,
and Exhaled Breath for Therapeutic Drug
Monitoring
Increasing antimicrobial resistance (AMR) is one of the biggest
threats to global health, food security, and development. AMR
has a high impact not only on prevention but also on treatment
of infectious diseases [58]. Antibiotic misuse and overuse are
the main accelerators of the development of AMR [59].
Approximately >30,000 deaths, >870,000 disability-adjusted
life years, and >670,000 infections were caused by multidrug
resistant organisms in the European Union in 2015 [60].
Antibiotic-resistant bacterial infections lead to a higher rate of
complications and a significantly higher need for resources [59].
Improved sanitation, hospital hygiene, infection precautions,
and antimicrobial stewardship are proposed solutions to reduce
AMR. An important aspect of antimicrobial stewardship is
therapeutic drug monitoring (TDM), which is already the
standard of care for the treatment with glycopeptides because
of their toxicity and TDM’s positive effects on patients’ clinical
J Med Internet Res 2021 | vol. 23 | iss. 8 | e25907 | p. 4https://www.jmir.org/2021/8/e25907
(page number not for citation purposes)
Brasier et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
outcomes [61]. Adult dose recommendations for antibiotics
account only barely for renal function, liver function, and
weight. Appropriate dosing is crucial, as previous evidence
indicates significant interpersonal variability in antibiotic serum
concentration and a low chance of achieving even the most
conservative pharmacological target [62]. Despite the advances
in TDM, a reliable, real-time, noninvasive, and lab-independent
monitoring approach is still not available [63,64].
Antibiotics in Sweat
Høiby et al [49,65] detected ciprofloxacin in sweat in 1997 and
certain β-lactam antibiotics in a follow-up study (Table 1) using
a microbiological agar diffusion method. Increasing amounts
of ciprofloxacin in axillary sweat were associated with the length
of antibiotic application time and remained detectable up to 28
hours after the last intake. Further, antibiotic concentrations in
sweat may even qualify as a surrogate marker for tissue
penetration in soft tissue infections as demonstrated by Brasier
et al [66] using ultra high-performance liquid chromatography
coupled with quadrupole mass spectrometry. Larger studies that
correlate antibiotic concentrations in sweat with clinical outcome
are needed to prove this concept.
Antibiotics in Saliva
Different classes of antibiotics have been detected in saliva so
far [50]. Intravenously administered cephalosporins as well as
orally administered cephalosporins, tetracycline, and
fluoroquinolones are excreted in concentrations above the
minimal inhibitory concentration (MIC) in sialadenitis (Table
1) [50,67,68]. However, detected by microbiological agar
diffusion, among other methods, phenoxymethylpenicillin was
shown to be secreted only in very low concentrations and was
therefore deemed not a reasonable treatment approach for
sialadenitis [50,67]. Macrolides are an additional class of
antibiotics that have been detected in saliva, but in the
aforementioned case of sialadenitis, their use has not been
indicated due to a high probability of developing antibiotic
resistances [69].
Antibiotics in Exhaled Breath
Herregodts et al [51] recruited 11 critically ill patients from the
intensive care unit to investigate the detectability of piperacillin
and meropenem in exhaled breath using ultra high-pressure
liquid chromatography high-resolution mass spectrometry (Table
1). After collecting breath using the ExaBreath, breath samples
were analyzed by mass spectrometry. Piperacillin was detected
at a median of 3083 pg/filter (988-203,895 pg/filter) and
meropenem at 21,168 pg/filter. However, antibiotic
concentrations of 2 of 11 patients were below the lower limit
of quantification. Further, antibiotic concentrations in exhaled
breath and blood did not correlate. The authors finally concluded
that antibiotics in exhaled breath potentially represent the
epithelial lining fluid concentrations. More investigations are
needed to better understand lung tissue concentrations rather
than comparing concentrations in exhaled breath to plasma [51].
Perspective on Digital Biomarkers for TDM
For sweat analysis, it is unclear if antibiotic concentrations in
sweat correlate with the concentrations in blood. However,
sweat concentrations may serve as a surrogate marker for
antibiotic tissue penetration. This may allow for targeting the
detected bacterial MIC obtained by microbial tissue samples in
the tissue [65,70]. TDM in saliva potentially shows a comparable
weakness, as correlating antibiotic concentrations in saliva and
blood remains too ambitious of a target. Still, monitoring
antibiotic concentrations in saliva may allow for ensuring
antibiotic concentrations above the MIC in bacterial sialadenitis
and provide an achievable target in the short term [50]. For
exhaled breath, lung diseases such as bacterial pneumonia or
pulmonary tuberculosis with a defined MIC seem to be a further
achievable monitoring approach.
Overall, it remains to be determined if antibiotic concentrations
in sweat, saliva, and exhaled breath correlate with antibiotic
concentrations in blood and may serve as systemic, noninvasive
TDM in the future. It is highly intuitive that local antibiotic
concentrations can potentially be used as a surrogate marker




From this perspective, we discussed the potential application
of novel smart biosensors in aTbc and antimicrobial multidrug
resistance, 2 urgent global issues in infectious diseases with
unmet needs. Emerging smart biosensors analyzing sweat,
saliva, and exhaled breath are increasingly available. These
biosensors enable noninvasive sample collection and provide
a remote, lab-independent patient monitoring system if
combined with smartphones. Moreover, integrating artificial
intelligence into the analysis process is a promising addition as
it has the potential to support significantly better disease
detection and discrimination [71]. Different sensor approaches
for on-skin sweat analysis, tooth-mounted sensors for saliva
analysis, and e-Noses for exhaled breath analysis are under
development at present [25,26,29]. Several specific molecular
markers such as the C1q subunit in sweat and interleukin-1β in
saliva were detected in patients with aTbc [45,47], thus opening
up a new pool of noninvasive biomarkers. Further, different
antimicrobials such as β-lactam antibiotics or tetracycline have
been detected in sweat, saliva, or exhaled breath [51,65,72].
AMR is a major global threat, and antibiotic stewardship is a
proven approach to reduce the development of bacterial
resistance [58,73]. Despite the promising approaches and
concepts that are considered for leveraging disease burden, only
the e-NOSE has been clinically implemented and has to be seen
as an exception in this explorative field [56].
A noninvasive, decentralized, lab-independent tool to monitor
health and disease is a promising approach to optimize patient
care in the future. However, major challenges, such as the lack
of technology readiness levels of biosensors, unknown
correlations, and high variability between concentrations in
sweat, saliva, exhaled breath, and blood, need to be addressed.
Before clinical investigation and implementation, a strict and
structured validation in laboratory settings is needed to provide
internal biosensor validity and clinically interpretable data.
Biosensors have to work in different environmental settings,
especially when it comes to endemic areas for aTbc, but for
J Med Internet Res 2021 | vol. 23 | iss. 8 | e25907 | p. 5https://www.jmir.org/2021/8/e25907
(page number not for citation purposes)
Brasier et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
TDM as well. Heretofore, high temperatures and high humidity
are main challenges to be addressed concerning sensor stability.
While biosensor development is expensive and raising funding
remains challenging, intensifying basic clinical research and
demonstrating clinical value are key to accelerating targeted
biosensor development and validation. Due to the decentralized,
lab-independent approach and ubiquitous application, smart
biosensors provide a scalable approach to impact the health care
of the future.
Further Limitations
Despite the high potential, a few issues remain and have been
keeping biosensors from broad clinical implementation, such
as low biomarker concentrations and unstable samples, as
discussed earlier. In addition, a variety of methods ranging from
microbiological agar diffusion methods to mass spectrometry
have been used for biofluid analysis. It remains to be determined
if the heterogeneously analyzed biomarkers will be detectable
by different smart biosensors, and challenges in biofluid
sampling need to be addressed during device development.
There are further challenging factors for each biofluid.
Sweat
Electrolyte concentrations in sweat are known to be dynamic
over time when exercising, and sweat rate is known to change
with alterations in body temperature [74]. Further, differences
in age, gender, and ethnicity have been described and need to
be further investigated [75].
Saliva
Several physiological factors influence saliva composition;
eating habits as well as oral health have also demonstrated a
significant impact [76,77]. Moreover, saliva can be contaminated
with blood, leading to concentration changes in oxidative stress
markers, for example, such as after brushing teeth [78].
Exhaled Breath
Detection of biomarkers in exhaled breath is influenced by
different habits. Diet and oral health have proven to challenge
breath analytics by varying the components [77,79]. Smoking
leads to further changes in the breath pattern [80].
Conclusion
We see great potential in applying smart biosensors to the
detection of next-generation digital biomarkers in infectious
diseases and provide the first noninvasive, lab-independent,
digital point-of-care diagnostics in the future. Modularly
combining sweat, saliva, and breath sensors with additional
biosensors to collect accelerometer data, heart rate, and body
temperature will enable more context-driven monitoring and
will support sample standardization. Moreover, if combined
with a GPS tracker, those devices allow instant interpretation
and monitoring of the spread of infections independently of
health care infrastructure on a global scale. To fully investigate
the potential of smartphone-based biosensors, more effort is
needed to develop, validate, and make those biosensors globally
available.
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